FBRX:NASDAQ, Forte Biosciences, Inc.

FBRX stock overview

Forte Biosciences, Inc. (FBRX:NASDAQ) closed at $76.99 on August 26, 2026, unchanged on the day. The stock trades 0.3% below its 52-week high of $77.20 and 661.5% above its 52-week low of $10.11. Forte Biosciences, Inc. is part of the Health Care sector.

Key figures

Price: $76.99
Day change: 0.00%
Volume: 1,399,801
Average volume: 1,511,439
Market cap: 1B+
52-week range: $10.11 – $77.20
50-day average: $55.18
200-day average: $33.25

Price action over the past year

In 252 trading sessions since October 21, 2025, FBRX closed higher on 114 days (45%). Its best day was July 9, 2026 (+78.33%) and its worst was January 28, 2026 (-15.99%). The stock moved 10% or more in a single session 19 times. It opened at least 5% above the previous day's high 1 time.

FBRX news

Aug 28, 2026: A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
Aug 27, 2026: Argenx (ENXTBR:ARGX) Completes Forte Biosciences Acquisition
Aug 12, 2026: Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders?
Aug 11, 2026: Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences
Aug 11, 2026: argenx (ENXTBR:ARGX) Stock Looks Fully Valued Despite Strong Returns And Deal Hopes
Aug 10, 2026: argenx (ENXTBR:ARGX) Is Considering A Forte Biosciences Acquisition
Aug 6, 2026: Are MKTX, SMTI, FBRX, LXFR Obtaining Fair Deals for their Shareholders?
Aug 6, 2026: argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

About Forte Biosciences, Inc.

Forte Biosciences Inc is a clinical-stage biopharmaceutical company, focused on dermatology. The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial.

Similar stocks

Find more stocks like FBRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.